Name | Value |
---|---|
Revenues | 0.0K |
Cost of Revenue | 0.0K |
Gross Profit | 0.0K |
Operating Expense | 8,078.0K |
Operating I/L | -8,078.0K |
Other Income/Expense | 1,044.0K |
Interest Income | 1,044.0K |
Pretax | -7,034.0K |
Income Tax Expense | -154.0K |
Net Income/Loss | -7,034.0K |
Rain Therapeutics Inc. is a clinical-stage precision oncology company focused on developing therapies targeting oncogenic drivers. Its lead product candidate, milademetan, is a small molecule oral inhibitor of mouse double minute 2, being evaluated in Phase 3 and Phase II clinical trials for various cancers, including liposarcoma, solid tumors, and intimal sarcoma. The company is also developing RAD52, a potential treatment for breast, ovarian, pancreatic, prostate, and other tumors. Rain Therapeutics Inc. generates revenue through the development and potential commercialization of its precision oncology therapies.